buprenorphine and naloxone

Prescribing practices that increase risk of opioid overdoseTwo studies, one from Prime Therapeutics and Stanford, reveal an alarming increase in overdose with concurrent use of opioids and benzodiazepines. Here’s how managed care can help.
Insurer: No more prior auths for opioid addiction medsAs part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.
Opioid addiction treatment in the ED better than referralsEmergency department (ED) patients with opioid dependence who receive a brief intervention and ED-initiated treatment with buprenorphine/naloxone and referral to primary care for 10-week follow up, are twice as likely to be engaged in addiction treatment at 30 days compared with standard referral and a brief intervention with a facilitated referral, according to a study published in JAMA.
AAAP: Data presented from largest combination buprenorphine/naloxone opioid dependence trial ever conducted in the USIn patients with opioid dependence, buprenorphine and naloxone (Zubsolv, Orexo) sublingual tablet (CIII) demonstrated comparable patient retention in treatment at days 3 and 15 versus generic buprenorphine and Suboxone film respectively, according to data presented at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry (AAAP) in Aventura, Fla.
Cost, use of opioid dependence treatment are increasing, spurring need for care management programsUnderstanding the patterns and costs associated with opioid dependence treatments is important when developing and improving care management programs for plan members, according to 2 studies by pharmacy benefit manager Prime Therapeutics LLC (Prime).
Buprenorphine tops list for pediatric poisoning requiring hospitalizationResearchers from the Centers for Disease Control and Prevention (CDC) and FDA undertook a study to determine the most commonly implicated active ingredients responsible for childhood poisonings that required emergency hospitalization in the hope of identifying prevention and intervention strategies. Buprenorphine and clonidine were the most common of 12 active ingredients that were found in 45.0% of these hospitalizations.
Knowledge of MATs key to overcoming opioid abuse challengesThe biggest challenge in tackling opioid abuse is lack of awareness and understanding of addictive diseases, as well as misinformation and negative perceptions of medication-assisted therapies (MATs), according to a recent opinion article published in the New England Journal of Medicine.
Sublingual agent approved for treatment of opioid dependenceThe U.S. Food and Drug Administration has approved a new tablet for use in helping patients with opioid dependence.
FDA approves sublingual agent for treatment of opioid dependenceFDA has approved a once-daily buprenorphine/naloxone (Zubsolv, Orexo) sublingual tablet CIII for use as maintenance treatment for people with opioid dependence. It should be used as part of a complete treatment plan that includes counseling and psychosocial support.
FDA approves sublingual agent for treatment of opioid dependence